NCT00326664 - AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell TumorChildhood Cerebral Anaplastic AstrocytomaChildhood Cerebral AstrocytomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood Infratentorial EpendymomaChildhood OligodendrogliomaChildhood Spinal Cord NeoplasmChildhood Supratentorial EpendymomaRecurrent Childhood Brain NeoplasmRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway Glioma

Interventions

DRUG

Cediranib Maleate

Given orally

Trial Locations (11)

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

27710

Duke University Medical Center, Durham

38105

Pediatric Brain Tumor Consortium, Memphis

St. Jude Children's Research Hospital, Memphis

60611

Lurie Children's Hospital-Chicago, Chicago

77030

Texas Children's Hospital, Houston

94115

UCSF Medical Center-Mount Zion, San Francisco

98105

Seattle Children's Hospital, Seattle

02115

Dana-Farber/Harvard Cancer Center, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH